newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

TVRD
  • Tvardi Therapeutics reported financial results for the first quarter ended March 31, 2026, with a net loss of $6.8 million.
  • Topline data for the Phase 1 healthy volunteer study of next-generation STAT3 inhibitor TTI-109 is anticipated in June 2026.
  • The company plans to announce the clinical development strategy for TTI-109 based on the June 2026 results.
  • Topline data from the Phase 1b/2 REVERT LIVER CANCER trial of TTI-101 in hepatocellular carcinoma is on track for the second half of 2026.
  • Interim analyses of the Phase 2 REVERT IPF trial showed TTI-101 achieved a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo.
  • TTI-101 treatment was associated with a 4.5-fold greater decline in the inflammatory cytokine IL-6 compared to placebo.
  • Research and development expenses increased to $4.9 million in Q1 2026 from $3.1 million in Q1 2025, driven by higher TTI-109 costs.
  • General and administrative expenses rose to $2.1 million in Q1 2026 from $1.2 million in Q1 2025 due to personnel costs \& professional fees.
  • Cash, cash equivalents, \& short-term investments totaled $25.0 million as of March 31, 2026.
  • The company's cash runway is sufficient to fund operations through clinical readouts \& into the fourth quarter of 2026.
  • Net loss per share was $(0.73) for Q1 2026, compared to $(3.72) for the same period in 2025.
  • TTI-109 is designed to offer improved tolerability via a prodrug profile \& enable broader development across STAT3-driven diseases.